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Abstract: Classical tumor suppressor gene discovery has largely involved linkage analysis and loss-of-heterozygosity 
(LOH) screens, followed by detailed mapping of relatively large chromosomal regions. Subsequent efforts made use of 
genome-wide PCR-based methods to detect rare homozygous deletions. More recently, high-resolution genomic arrays 
have been applied to cancer gene discovery. However, accurate characterization of regions of genomic loss is particularly 
challenging due to sample heterogeneity, the small size of deleted regions and the high frequency of germline copy num-
ber polymorphisms. Here, we review the application of genome-wide copy number analysis to the specific problem of 
identifying tumor suppressor genes. 
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INTRODUCTION 
  Ever since the seminal demonstration by Bishop and 
Varmus more than 30 years ago that transforming oncogenes 
arise from normal cellular genes, the discovery of additional 
cancer-specific mutations has fueled the hope of diagnosing 
and treating cancer with tumor-specific modalities [1]. How-
ever, although identifying the driving genetic lesions for 
select cancers has led to improved diagnostics and therapies 
in some cases, the total number of patients who benefit from 
these approaches remains a relatively small fraction of all 
patients suffering from cancer [2-7]. To identify additional 
cancer genes, a variety of unbiased, genome-wide ap-
proaches have emerged that can detect a large fraction of the 
genetic differences between human tumors and their normal 
tissue counterparts. Among these, the development of array-
based genomic hybridization technologies has paved the way 
for interrogating an ever increasing density of probes for 
markers distributed across the cancer genome for increases 
and decreases in intensity suggestive of somatic alterations 
causally related to tumor formation. To facilitate the analysis 
of the very large datasets generated by such methodologies, 
several automated approaches have been developed to sys-
tematically refine the number of candidate cancer genes for 
further genetic and functional characterization. These have 
led to the nomination of numerous candidates whose bio-
logical significance requires deeper genetic analysis and ro-
bust functional validation. Here, we review the application of 
array-based gene copy number analysis to the specific prob-
lem of identifying tumor suppressor genes. We start by re-
viewing the discovery of bona fide tumor suppressor genes 
for common themes that may guide the interpretation of   
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candidates identified through genomic approaches. Next, we 
review the development of genome-wide approaches aimed at 
the global identification of copy number alterations in cancer. 
We then focus on array-based copy number analysis and re-
view the major steps in converting probe-level intensity 
measurements to deleted regions harboring candidate tumor 
suppressor genes. Finally, we discuss specific examples of 
new candidate tumor suppressor genes identified through 
genome-wide copy number analysis and we summarize the 
evidence for their involvement in human cancer. 
DISCOVERING  BONA FIDE TUMOR SUPPRESSOR 
GENES 
  Historically, genetic approaches for discovering tumor 
suppressor genes (TSGs) have required validating several 
candidate genes contained within a large chromosomal re-
gion implicated by linkage analysis in families afflicted with 
cancer predisposition syndromes or targeted by tumor-
specific allelic loss (so called loss-of-heterozygosity/LOH). 
Several common themes have emerged from these efforts 
(Table 1). 
1. Rare Cases Associated with Focal (Homozygous) Dele-
tions can be Informative 
  In the “pre-genomic” era, the chromosomal regions im-
plicated in cancer by linkage analysis or LOH screens were 
usually very large (on the order of many megabases), and 
would therefore normally require many iterative steps of 
genotyping with many more genetic markers, and eventually, 
the sequencing of many candidate genes to detect inactivat-
ing mutations indicative of the targeted TSG. In most cases, 
uncovering the targeted gene relied on the discovery of rare 
cases with focal deletions (germline heterozygous deletions 
for genes predisposing to cancer and somatic tumor-specific 
homozygous deletions for sporadic tumors) encompassing 
one or a few genes (Table 1). In fact, the recognition of the 298    Current Genomics, 2010, Vol. 11, No. 5  Rothenberg and Settleman 
value of tumor-specific focal homozygous deletions to im-
plicate new TSGs provided much of the impetus for the de-
velopment of unbiased, genome-wide approaches for detect-
ing them (see discussion below) [8-11]. 
2. Very Small Deletions can Inactivate Genes 
  In theory, deletion of a single coding nucleotide will 
cause a frameshift mutation that can lead to gene inactivation 
through protein truncation. Although detecting single nu-
cleotide deletions essentially requires single nucleotide se-
quencing, very small deletions encompassing one or a few 
genes have been instrumental in cloning many important 
TSGs (Table 1) [12-22]. Identifying the APC gene relied on 
an analysis of two cases with focal deletions spanning just 
three genes [14,16]. Focal homozygous deletions in cancer 
cell lines were instrumental in the identification of INK4A/B 
as one of the most common targets of genetic inactivation in 
human cancers [17,22]. Loss of heterozygosity affecting 
nearly the entire long arm of chromosome 10 is extremely 
common in primary gliomas, and the identification of PTEN 
was made possible by the discovery of rare cell lines with 
intragenic homozygous deletions affecting PTEN  and no 
other flanking genes [18,20]. A deletion of just 25 nucleo-
tides (spanning an exon-intron boundary and leading to aber-
rant splicing) was critical to implicating WT1 in Wilms’ tu-
mor [12,15]. As can be seen in Fig. (1), a high resolution 
scan of genomic loci known to be targeted by homozygous 
deletions reveals both broad deletions encompassing several 
genes and very focal, intragenic deletions disrupting just one 
or a few coding exons and therefore directly implicating the 
individual, targeted gene.  
3. Detecting Homozygous Deletions is Extremely Sensi-
tive to Background Effects and Stromal Admixture 
  Each of the examples described above relied on the pres-
ence of the deletion in every cell within the analyzed sam-
ples, either because the deletion was present in the germline 
(e.g. for cancer predisposing TSGs) [12,14-17] or because 
cancer cell lines or primary cultures (presumably, clonally-
derived) were utilized (for somatically inactivated TSGs) 
[17,20]. For both PCR-based approaches and, as discussed 
below, array-based copy number analyses, the detection of 
deletions may be particularly confounded by the presence of 
mixed tumor-associated stroma, since the presence of non-
cancer diploid genomes can lead to preferential detection of 
the non-deleted, normal DNA [8,23]. In addition, accurately 
measuring genomic losses is inherently more difficult than 
detecting amplifications, since losses are limited to only one 
or two copies, and any residual signal will be extremely 
close to the lower limits of detection of the platform being 
utilized. 
  Each of these features may significantly impact the dis-
covery of candidate TSGs by genome-wide copy number 
analysis. Small deletions consisting of one or a few genomic 
probes with hybridization signals barely above background 
may easily be obscured within the significant noise associ-
ated with the simultaneous measurement of literally hun-
dreds of thousands of genetic markers. The invariable pres-
ence of stromal cells in primary tumor specimens may fur-
ther decrease the ability to detect discrete losses indicative of 
novel TSGs. Therefore, the specific consideration of back-
ground effects and stromal admixture by individual genomic 
platforms and computational algorithms is critical for estab-
Table 1.  Examples of Bona fide Tumor Suppressor Genes Identified by Focal Deletions 
Gene  Methodology  Size of minimal deletion  Reference 
CDKN2A/B  Deletion mapping  intragenic  [17,22] 
Rb1  Linkage* intragenic  [13] 
APC  Linkage   three genes  [14,16] 
WT1  Linkage   25 nucleotides  [12,15] 
SMAD4  LOH 2Mb [21] 
PTEN  RDA, LOH  intragenic  [18,20] 
WTX  array CGH  1-3 oligonucleotide probes  [19] 
*Homozygous deletions in sporadic tumors. 
 
 
 
 
 
 
 
Fig. (1). Homozygous deletions of CDKN2A/B in human cancer cell lines. Heatmap of log[2] copy number demonstrates targeting of this 
locus by both broad homozygous deletions in blue (red indicates gains) affecting neighboring genes (rightmost samples) and intragenic ho-
mozygous deletions (leftmost samples) that remove individual coding exons without impacting neighboring genes. This figure was adapted 
from [85]. Genomic Discovery of Tumor Suppressor Genes  Current Genomics, 2010, Vol. 11, No. 5    299 
lishing candidate TSGs proposed on the basis of genome-
wide copy number analyses. The sensitivity of deletions to 
these confounding effects may be contrasted with chromo-
somal regions of copy number gain/amplification that may 
harbor novel oncogenes. Unlike inactivating deletions, gains 
that may lead to oncogene activation through increased ex-
pression must extend at least the entire length of the targeted 
gene (and in practice often span several genes). In addition, 
the degree of amplification may be many times the normal 
diploid copy number and therefore will be less subject to the 
confounding effects of background signal and admixed 
stroma.  
IDENTIFYING TUMOR SUPPRESSOR GENES BY 
GENOME-WIDE COPY NUMBER ANALYSIS  
PCR-Based Approaches 
  Initial unbiased efforts to screen the cancer genome for 
regions of genomic loss that potentially harbor tumor sup-
pressor genes utilized PCR to enrich the DNA sequences 
present in normal genomic DNA that were absent from tu-
mor DNA. Among several methods developed to identify the 
differences between two complex genomes, representation 
differentiation analysis (RDA) has been most successfully 
used to identify novel TSGs [8,9]. The RDA methodology 
consists of restriction digestion, subtractive hybridization 
and selective PCR amplification to generate simplified “rep-
resentations” of the genome using mixed tumor and matched 
normal samples. RDA is extremely powerful for detecting 
rare differences in largely identical genomes (e.g. viral se-
quences, tumor samples with matched normal DNA avail-
able). RDA was instrumental in the cloning of PTEN, 
BRCA2  and other candidate tumor suppressor genes 
[18,24,25]. However, several features have complicated its 
use as a screening tool for cancer gene identification: (1) 
technical complexity (which limits the number of samples 
that can be analyzed); (2) genomic instability in solid tu-
mors, leading to the detection of many candidate regions that 
appear to be decreased in tumor DNA (compared to normal); 
(3) copy number polymorphisms, which, in the absence of 
matched normal tissue DNA, lead to many false positives; 
and (4) the fact that candidate regions are identified en 
masse, and must be subsequently deconvoluted to permit 
validation of individual loci. Nevertheless, several improve-
ments have been made to increase the power of RDA. Using 
tumor genomic DNA from genetically engineered mouse 
models and strain-matched normal DNA can decrease the 
impact of germline copy number variation, while combining 
the initial subtraction and amplification steps with array-
based hybridization permits rapid deconvolution of complex 
mixtures of differentially amplified loci (representational 
oligonucleotide array analysis/ROMA—see below) [25,26].  
MICROARRAY-BASED COMPARATIVE GENOMIC 
HYBRIDIZATION (CGH) 
  The initial demonstration of tumor-specific genomic im-
balance by traditional metaphase karyotyping has led to in-
creasingly sensitive methods for detecting cytogenetic ab-
normalities in cancer. With comparative genomic hybridiza-
tion (CGH), differentially fluorophore-labelled tumor (e.g. 
fluorescein) and normal (e.g. rhodamine) DNA are co-
hybridized to normal metaphase spreads in the presence of 
unlabelled Cot-1 DNA (to block off-target binding to repeti-
tive sequences), permitting quantitative detection of discrete 
regions of chromosomal gain or loss (as determined by the 
ratio of fluorescein-to-rhodamine fluorescence) [27]. CGH 
has permitted the cataloguing of human tumors by recurrent 
regions of gains and losses that correlate with clinical fea-
tures and have helped to pinpoint causative cancer genes 
[28]. However, the use of metaphase chromosomes to local-
ize genomic alterations and the high complexity of the 
probes limit its detection resolution to ~20Mb. A related 
methodology, spectral karyotyping (SKY), combines multi-
color fluorescence in situ hybridization with spectral analysis 
that has been particularly valuable for detecting chromoso-
mal translocations, though still with limited resolution (1-
2Mb) [28]. 
  The development of DNA microarrays, initially for 
mRNA expression analysis, provided two significant advan-
tages over traditional CGH: (1) increased resolution, limited 
only by the density of genomic probes on the array (expected 
to increase further with the completion of the human genome 
sequencing project) [29,30]; and (2) highly parallel analysis, 
permitting the identification of individual candidate regions 
(for subsequent validation) in a single step. Initial applica-
tions of array-based CGH used large insert genomic DNA 
(e.g. BAC) clones that provided higher resolution (~40kB) 
than traditional CGH and the quantitative measurement of 
DNA gains and losses. However, increasing the resolution 
further was limited by probe complexity as well as the chem-
istry used to couple the genomic probes to the array surface, 
such that smaller probes were not bound effectively 
[10,31,32]. The development of complementary DNA 
(cDNA) microarrays and their application to the determina-
tion of DNA copy-number variation in human tumor samples 
represented a significant advance in genomic analysis of 
tumors by providing the first genome-wide view of copy 
number alterations at gene resolution [11,30]. In addition, 
the demonstrated ability to robustly detect single and two-
copy losses (despite the much greater complexity of genomic 
DNA compared to cellular mRNA) is critical to detecting 
tumor suppressor genes, since genomic losses are discrete 
and limited in amplitude (e.g. loss of one or both alleles) 
compared to gains [11]. Another important advantage of 
cDNA microarray-based CGH is the ability to characterize 
both copy number and gene expression patterns in parallel in 
the same samples and on the same array platform, enabling 
candidate genes to be narrowed to those whose genomic gain 
or loss is associated with corresponding changes in gene 
expression (and thus are the likely targets of the alteration). 
  Arrays of oligonucleotide probes were developed in par-
allel to cDNA arrays [26]. The major platforms in current 
use consist of arrayed probes of 60-70 nucleotides for CGH 
(e.g. Agilent); or 25 nucleotide probes (e.g. Affymetrix), on 
which tumor and reference hybridizations are carried out 
separately, with copy number inferred indirectly by compari-
son. In addition to determining copy number, Affymetrix 
arrays are designed to detect single nucleotide polymor-
phisms (SNPs), and therefore, can be used for simultaneous 
determination of copy number and LOH at every analyzed 
locus from a single hybridization, even in the absence of a 
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tion of the actual genetic mechanism underlying LOH events 
(e.g. copy-reducing from copy-neutral), and could reveal 
additional samples for deeper sequencing to identify inacti-
vating mutations (e.g. point mutations) not apparent from 
copy number analysis. An important feature of most oli-
gonucleotide probe-based methodologies is the requirement 
that the complexities of the analyzed genomes be signifi-
cantly reduced (by restriction digest and PCR) to permit ac-
curate hybridization. These approaches may therefore be 
quite sensitive to SNPs (that prevent restriction enzyme 
cleavage) and PCR artifacts that can contribute to misidenti-
fication of altered loci. Despite these potential limitations, 
oligonucleotide arrays provide increasingly high resolution 
and are capable of detecting alterations located within inter-
genic and nongenic regions of the genome, and have there-
fore become the preferred platform for gene expression and 
copy number analysis.  
 Additional  methodologies for copy number analysis in-
clude bead-based oligonucleotide arrays (e.g. Illumina) and 
digital karyotyping [34]. The former is very similar to arrays 
of chemically immobilized oligonucleotides but uses silica 
bead-based capture technology with more robust and uni-
form display of probe oligonucleotides, and therefore yields 
more accurate and complete measurement of probe hybridi-
zation (and furthermore does not require PCR-based 
representation generation or pre-labeling of genomic DNA). 
The latter approach, which utilizes combinations of 
restriction enzymes and PCR to generate 21-bp tags from 
genomic DNA that are concatamerized and sequenced to 
determine location and tag density and then computationally 
mapped, has been used to isolate candidate cancer genes, but 
may be limited in scope by the requirement for labor-
intensive deep sequencing and decreased mapping resolution 
[35]. Finally, the feasibility of using single-molecule 
sequencing for identifying focal gains and losses based on 
density of reads has recently been demonstrated [36], 
although, like digital karyotyping, given cost and labor, is 
currently limited to analysis of only a few samples in any 
given study. A summary of the major array copy number 
analysis platforms is provided in Fig. (2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Comparison of major copy number analysis platforms. With traditional array CGH (left), genomic DNA isolated from tumor and 
normal samples is labeled with unique fluorophores (e.g. Cy5 (red) for tumor and Cy3 (green) for normal and then cohybridized to a single 
array consisting of cDNAs or 60-70mer oligonucleotides. Genomic losses are identified as an abundance of Cy3 (green) fluorescence, gains 
as an excess of Cy5 (red) fluorescence. With SNP arrays (right), tumor and normal samples are labeled and hybridized in parallel to different 
arrays. Each SNP probe consists of four sets of 25mer oligonucleotides, two each for the major (A) and minor (B) alleles, one perfectly 
matched (A,B) and one mismatched (A',B'). Copy number is determined in silico by accounting for the total hybridization signal from each 
perfectly matched probe, normalized to the background hybridization from the mismatched probes and the average hybridization signal from 
the normal samples. An abundance of signal (increasing blue) in normal relative to tumor marks genomic losses, in tumor relative to normal, 
gains.  Genomic Discovery of Tumor Suppressor Genes  Current Genomics, 2010, Vol. 11, No. 5    301 
AUTOMATED DISCOVERY OF AMPLIFICATIONS 
AND DELETIONS 
  An explosion in the generation of array-based copy num-
ber data sets has led to an increasing number of computa-
tional approaches for deriving information about candidate 
cancer genes from probe-level data. The following section 
reviews the major steps in converting probe-level intensity 
data into regions of copy number alteration that may harbor 
cancer genes.  
Converting Hybridization Intensity to Copy Number 
  Methods for converting raw probe intensity data to copy 
number information depend on the microarray platform (e.g. 
cDNA or oligonucleotide, CGH versus independent hybridi-
zation of controls). In general, following quality control and 
correction for background array noise, the hybridization sig-
nal from each probe on the array is normalized to the corre-
sponding signal from a known or inferred diploid genome(s). 
SNP arrays provide probe-specific estimates of non-specific 
hybridization by incorporating single nucleotide mismatched 
probes (for each matched SNP probe) that permit probe-
specific estimation of non-specific hybridization (copy num-
ber is determined using model-based estimates that account 
for the signal from both matched and mismatched probes 
[37]). To permit more robust comparison between separately 
arrayed samples (that may be subjected to systematic, array-
specific differences in hybridization conditions), the hybridi-
zation intensity and/or normalized copy number for each 
probe in each sample is usually “centered” to the median 
value of all or select (e.g. “invariant”) probes on the particu-
lar array (arrays processed in the same batch may also be 
centered to the array with the median overall intensity among 
the arrays in the batch). 
  The choice of reference samples can significantly impact 
the accuracy of copy number measurements. The use of a 
single matched (e.g. from the same patient) reference sample 
to normalize each tumor sample may reduce the frequency of 
false-positives by controlling for germline copy number 
variations (see below); however, variable sample quality can 
make comparisons among different tumor samples more 
difficult [38]. Therefore, even when matched reference sam-
ples are available, a single reference consisting of multiple 
normal samples is often used. In the case of array CGH, 
these may be pooled prior to labeling and cohybridization (to 
each tumor sample). For SNP arrays, the “normals” are ar-
rayed individually and then pooled computationally, most 
commonly by normalizing each sample probe to the average 
single intensity of that probe in the reference samples. Some 
authors have recommended the use of a standardized collec-
tion of normal reference samples, the polymorphic features 
of which have been extensively characterized (e.g., derived 
from the HapMap Project) [38].  
Converting Probe-Level Signals to Genomic Copy Num-
ber 
  Although in theory the copy number at each genetic locus 
should be defined by integer values (e.g. single copy loss, 
homozygous deletion or gain), intermediate values are more 
typically observed in array analyses. Sources of “noisy” 
copy number measurements include polymorphisms present 
in the arrayed DNA, probe sequence-specific variability in 
hybridization kinetics, incorrectly mapped probe locations 
and stromal admixture. A variety of computational methods 
have been developed to “automatically” delineate genomic 
regions of gains from probe-level data [26,39-49]. Although 
the mathematics differs among the individual methods, the 
general approach is: (1) sample by sample and chromosome 
by chromosome, combine data from neighboring markers 
with the same underlying copy number; (2) identify statisti-
cally significant transitions in copy number for neighboring 
probes using a reference distribution from normal tissue hy-
bridizations or through permutation testing; and (3) repeat 
iteratively until significance is maximized for each copy 
number transition, producing genome “segments” consisting 
of variable numbers of contiguous probes with statistically 
similar copy number. Segmentation algorithms are essential 
for simplifying large datasets consisting of many samples to 
a manageable number of discrete alterations for subsequent 
analysis. However, to identify tumor suppressor genes, it is 
important to consider how each algorithm handles two fea-
tures of variability in probe-level data, smoothing and small 
segments. 
Smoothing 
  Smoothing is the process in which each segment is as-
signed a copy number equal to the average of all of the 
probes it contains. Smoothing may reduce “noise” in the data 
by reducing the appearance of underlying probe-to-probe 
variability in hybridization, thereby increasing sensitivity 
and specificity [11]. However, smoothing may obscure pre-
cise detection of alteration boundaries and very small homo-
zygous deletions comprised of one or a few probes, particu-
larly when a homozygous deletion arises from one large-
scale and one focal allelic loss (Fig. 3A).  
Small Segments 
  The problem of individual outlier probes was initially 
appreciated from the comparison of normal-normal hybridi-
zations using oligonucleotide array-based CGH, in which 
many stand-alone probes appear as minor losses and gains, 
manifesting as a “shell” of probes appearing primarily as 
many single-copy losses and gains [26]. These outlier probes 
consist of false-positive aberrations--hybridization artifacts, 
incorrectly mapped probes, SNPs that create or destroy sites 
for cleavage by the enzyme used to fragment the genomic 
DNA before hybridization—and potentially true positive, 
focal losses (and gains). Most algorithms employ methods to 
filter out potential outliers via  smoothing, “fusion” to the 
closest large aberration, or by simply ignoring segments 
comprised of less than a pre-specified number of probes 
(usually 5-8) [26,50-53]. However, depending on the density 
of probes, true copy number losses comprising one or a few 
probes could in fact span many kilobases, and therefore inac-
tivate the affected gene (Fig. 1).  
Scoring an Altered Region as Deleted 
  Scoring of losses requires a careful consideration of al-
teration amplitude. Most approaches pre-specify fixed copy 
number thresholds, either empirically or based on the distri-
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segments with copy numbers falling outside of the threshold 
are considered significantly altered [51,52,54]. Some inves-
tigators apply multiple thresholds to distinguish low-level 
gains from high-level amplification and single copy losses 
from homozygous deletions [38,50].  
  Scoring deleted regions with such fixed thresholds is 
made particularly challenging by the inherent difficulty in 
accurately measuring the true signal (above background) 
from low intensity hybridizations. Although a deletion 
should result in 50% (heterozygous) or total (homozygous) 
loss of signal from the resident probes, even for homogene-
ous tumor cell populations (e.g. cell lines), significant probe-
to-probe variation in copy number is observed across known 
genomic deletions, a result of several factors, including noisy 
measurements at the lower end of the dynamic range, 
smoothing, tumor heterogeneity, allele-specific copy number 
changes and negative skew in the distribution of copy num-
ber around the diploid peak [38]. Accurate scoring of dele-
tions may be particularly confounded by the presence of con-
taminating stromal DNA in primary tumor specimens. Al-
though most approaches exclude samples with < ~70% tu-
mor cells, scoring may vary between pathologists and may 
not account for polyclonal tumor cell populations or exten-
sively admixed stroma. The consequences of stromal admix-
ture have been extensively characterized in “mixing experi-
ments”; the data demonstrate that detection of homozygous 
deletions is extremely dependent on tumor purity [23]. 
Methods to minimize the effect of stromal admixture include 
tissue micro-dissection or the use of flow cytometry to sepa-
rate aneuploid from diploid cells in patient samples [26,55].  
Germline Copy Number Variants 
  Germline genomic variation, associated primarily with 
short (0.1-1kB) insertions and deletions (Indels) and longer 
(>1kB) gains and losses (copy number variants/CNVs), has 
been demonstrated in ~12% of the genome, at frequencies as 
high as 10% of the normal population, and these often in-
volve gene coding sequences (Fig. 3B) [26,55]. A moderate 
correlation between CNV regions and segmental duplica-
tions has led to the suggestion that they may occur in regions 
of the genome prone to recombination events (and therefore 
could arise de novo). In addition, a recent study suggests that 
the majority of the copy number differences between any 
two individuals arise from a limited set of common, inherited 
polymorphisms [56]. Although germline copy number varia-
tions have been demonstrated to contribute to disease sus-
ceptibility, the contribution of individual polymorphisms to 
any particular phenotype is (so far) small [57-59]. Whether 
germline copy number losses predispose to tumor formation 
is not yet known, although, as for other diseases, the overall 
contribution of any individual variant to tumorigenesis may 
be small. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Detecting focal losses by copy number analysis. (a) The effect of median smoothing of probe copy number is demonstrated for a 
theoretical locus targeted by a focal homozygous deletion comprised of overlapping large (boundaries indicated with black arrows) and focal 
(paired gray arrows) alleic losses. As the probe window size for smoothing is increased, the focal deletion becomes obscured by the signal 
from surrounding probes. (b) Heatmap and graphical display of log{2} copy number for normal tissues. Genomic DNA from six normal 
samples (peripheral blood mononuclear cells) was hybridized to Affymetrix Human Mapping 250K Sty Arrays and analyzed with dCHIP 
software (http://www.hsph.harvard.edu/~cli/complab/dchip/). Shown is a portion of chromosome 19 demonstrating a focal loss spanning 
several probes (asterisk) in one sample (indicated by black arrow), consistent with a germline copy number polymorphism. (c) higher resolu-
tion view of region indicated by asterisk.  Genomic Discovery of Tumor Suppressor Genes  Current Genomics, 2010, Vol. 11, No. 5    303 
  CNVs present a unique challenge to accurately identify-
ing tumor suppressor loci because a germline deletion de-
tected in a tumor by copy number analysis may be incor-
rectly considered to be of somatic origin. Furthermore, de-
pending on the background rate of generation of genomic 
losses, a pre-existing heterozygous copy number loss could 
be converted to a homozygous deletion through somatic loss 
of the other allele (yet this still may represent a passenger 
mutation). Homozygous deletions overlapping pre-existing 
heterozygous CNVs have been observed, although the fre-
quency at which this occurs has not been systematically 
determined [26].  
  Normalizing each tumor sample to matched normal tissue 
can help to establish the germline or somatic origin of each 
tumor alteration, but is impractical for the reasons discussed 
above. Therefore, most studies manage the potentially con-
founding influence of common CNVs by eliminating from 
consideration any altered probes that map to known CNVs, 
or by excluding entirely genes overlapping with frequent 
CNVs, based on the growing database of described genomic 
variants [55]. Nevertheless, many candidate tumor suppres-
sor genes proposed on the basis of copy number analyses are 
also marked by frequent germline variation (Table 2); this 
may complicate determining the true contribution to tumor 
formation (see discussion of individual candidate genes be-
low).  
Table 2.  Frequency of Germline Genomic Variants for Bona 
fide and Putative Tumor Suppressor Genes 
Candidate Cytoband  CNV    INDEL 
MSH2  2p21 0 1* 
TGFBR2  3p24.1 0  1* 
CDKN2A/B  9p21.3 1  0 
PTEN  10q23.31 0  0 
WT1  11p13 1  0 
RB1  13q14.2 0  2* 
TP53  17p13.1 0  0 
NF1  17q11.2 0  0 
SMAD4  18q21.1 0  0 
NF2  22q12.1 0  0 
WTX  Xq11.1 0  0 
FHIT  3p14.2 16  4 
PARK2  6q26 35 10 
CSMD1  8p23.2 60  31 
PTPRD  9p23 30 19 
WWOX  16q23.1 18  3 
CNV: copy number; INDEL: insertion-deletion. 
*intronic. 
Source: Database of Genomic Variants [55]. 
 
Estimating the Background Rate of Aberration 
  Early attempts to define altered genomic regions poten-
tially harboring novel cancer genes prioritized regions with 
recurrent alteration—those detected in more than one sample 
[23,40,60]. However, depending on underlying mutation 
rates and the number of samples analyzed, even recurrent 
alterations could represent byproducts of tumor genome in-
stability rather than true driver aberrations. Therefore, as 
with determining the underlying rate of point mutations in 
tumor genome re-sequencing studies, more recent copy 
number analyses have attempted to estimate the background 
rate of mutation as the basis for determining statistical sig-
nificance. Estimating the rate of point mutations is most of-
ten achieved by determining the rate of silent mutations 
within coding sequences and/or point mutations in non-gene 
containing regions of the genome (these are presumed to be 
phenotypically neutral and therefore not acted upon by selec-
tion) [61-65]. Furthermore, the wealth of recently generated 
tumor resequencing data has permitted the influence of nu-
cleotide context on the rates of mutation to be incorporated 
into models of the background mutation rate. By contrast, 
the phenotypic consequences of alteration location, size, 
amplitude and sequence are less well understood. Two recent 
studies described genome features of human cancer cell lines 
associated with a higher rate of homozygous deletions 
(which also varied depending on the tissue of origin) [66,67]. 
This could suggest that many recurrent homozygous dele-
tions detected in human cancer genomes lie within fragile 
sites prone to genomic losses rather than marking true cancer 
genes, thus complicating the identification of bona fide tu-
mor suppressor genes on the basis of genome-wide deletion 
analysis. 
  Given this uncertainty, the most common strategy is to 
approximate the background rate (by binomial distribution or 
permutation testing) with the overall rate of alterations, as-
suming random distribution across the genome 
[38,51,53,68,69]. Most approaches are inherently conserva-
tive, e.g. they overestimate the background rate because they 
include alterations affecting bona fide cancer genes (which 
are likely true driving alterations rather than nonspecific pas-
sengers). Consequently, this approach could fail to detect 
true driver aberrations that occur at relatively lower fre-
quency. 
Considering the Degree of Copy Number Change 
  Some approaches incorporate alteration amplitude (how 
many copies of a gene are gained or lost) into the determina-
tion of significance (e.g. together with the frequency of the 
observed alteration). The general approach is to set very low 
thresholds for initial scoring of gains and losses, followed by 
weighting of each alteration by the actual amplitude. Such 
weighting may be carried out using a continuous scale, or 
with discrete classes (e.g. single-copy gain, single-copy loss, 
amplification, or homozygous deletion) [38,50,51]. For am-
plifications, this may be useful; thus, the dynamic range of 
gains extends from single copy to more than 30, and, in gen-
eral, the degree of amplification correlates with overexpres-
sion at the protein level (and thus the degree of activation of 
the targeted gene). However, for deletions, there are only 
two amplitudes: loss of one or both copies (what is the real 
meaning of commonly observed noninteger copy number 
values, and how should they be weighted?) Therefore, de-
pending on the relative contribution of alteration frequency 
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particular genomic losses could potentially be under- or 
over-estimated. 
Finding the Individual Gene(s) Targeted by a Deletion 
  Although validating candidate genes targeted by very 
focal deletions is relatively straightforward, prioritizing 
many candidate genes encompassed by a single large dele-
tion is more challenging. Focusing on the minimal common 
region (MCR) targeted by overlapping deletions can narrow 
the number of candidate genes, as can parallel gene expres-
sion analysis to identify the subset of genes within a deleted 
region that are expressed at lower levels [50]. In addition, 
choosing the subset of probes within an MCR with the great-
est (or most significant) amplitude of copy number aberra-
tion has been used to further narrow the candidate list [51]. 
However, this requires that the probes overlying the targeted 
gene are also the most aberrant, an assumption that has been 
challenged by examining the characteristics of probes mark-
ing  bona fide tumor suppressor genes [38]. A particularly 
novel approach to determining whether a large alteration 
may harbor more than one target is to remove (“peel-off”) 
the most aberrant (significant) subset of contiguous probes, 
and to recalculate the significance of the remaining probes 
and determine whether any other subset of contiguous probes 
still reaches significance [51,52].  
CANDIDATE NOVEL TUMOR SUPPRESSOR GENES 
IDENTIFIED BY COPY NUMBER ANALYSIS 
  Having reviewed the major steps involved in narrowing 
thousands of probe intensities to a manageable number of 
candidate tumor suppressor genes, we now discuss examples 
of specific candidate tumor suppressor genes identified on 
the basis of large-scale array-based copy number analyses. 
Although the list of candidate genes discussed is by no 
means comprehensive, our primary goal is illustrate how 
each candidate was selected and to critically evaluate the 
data subsequently obtained from deeper genetic and func-
tional validation studies supporting a bona fide tumor sup-
pressor function for each candidate.  
Novel Glioma Tumor Suppressor Genes: PARK2 and 
PTPRD 
  A comprehensive approach to converting probe-level 
intensity data to candidate cancer regions and genes has been 
utilized to characterize several cancer genomes, including 
those from gliomas, lung adenocarcinomas and renal cell 
carcinomas [51,52,54,70]. The approach, known as Genomic 
Identification of Significant Targets in Cancer, or GISTIC, 
illustrates many of the steps of analysis outlined in the first 
part of this review. First, a series of data preprocessing steps 
log2-transforms and median centers the probe intensity data 
(sample by sample), corrects for systematic variation in 
probe intensities apparent in subsets of arrays (“batch” ef-
fects), converts probe intensity to copy number by normaliz-
ing each tumor sample only to the subset of (unmatched) 
normal samples with similar overall probe behavior (“tan-
gent” normalization), and removes duplicate samples and 
samples contaminated by significant stromal admixture. 
Next, probe-level copy number data is segmented (with the 
GLAD segmentation algorithm) and each segment is median 
smoothed (e.g. each probe is assigned a new copy number 
value equal to the median value for all probes contained in 
the same segment) [42]. Third, probes overlapping polymor-
phic regions as identified in the Database of Genomic Vari-
ants are removed [55] Fourth, each probe is weighted by the 
G-score, the product of aberration frequency and average 
amplitude across all samples, assigned significance by com-
paring the individual G-score to that obtained with an ap-
proximation of the null distribution, and the resulting p-
values corrected for multiple comparisons to generate q-
values. Probes with q-values <0.25 are considered to be sig-
nificant. Finally, the candidate gene(s) is determined from 
the subset of probe(s) with the lowest q-values in each re-
gion. 
  Notable findings from GISTIC analysis with particular 
relevant to finding new TSGs include:  
(1)  The background rate of deletions is higher than the 
background rate of amplifications. Therefore, dele-
tions must occur at higher frequencies than amplifica-
tions to reach statistical significance (based on the G-
score statistic described above). The background rate 
in gliomas is particularly high—every region of the 
genome is altered in at least one sample.  
(2)  Both “broad” (at least a whole chromosome arm) and 
focal deletions are identified, with broad losses occur-
ring substantially more frequently than focal losses.  
(3)  In the glioma studies, the frequency of recurrence of 
focal alterations decreases with increasing size of the 
alteration, up until a size equal to ~90% of a chromo-
some arm, at which point the trend reverses. This 
could have important implications for the particular 
model used to estimate the background rate of altera-
tion, since that rate may vary depending on whether 
the alteration is large or small. 
(4) Several  bona fide glioma and lung adenocarcinoma 
tumor suppressor genes were identified, including 
CDKN2A/B, PTEN, RB1 and CHD5 (glioma) and 
CDKN2A/B, TP53, STK11, PTEN and RB1 (lung can-
cer). 
(5)  Several deleted regions are not associated with known 
cancer related genes. Although the majority of these 
encompass many genes, the peak regions correspond-
ing to several are limited to one or a few candidates.  
(6)  The GISTIC method may be remarkably robust for a 
variety of studies and platforms. In the initial publica-
tion, when the data from two previous glioma studies 
(comprising different samples and array platforms) 
was reanalyzed with GISTIC, the candidate regions 
identified by each study were remarkably concordant, 
even though there was little overlap in the candidate 
regions when the original algorithms and prioritiza-
tion schemes were utilized [71,72]. The combined 
analysis of samples from all three studies permitted 
adjustment of the peak regions in the previously iden-
tified intervals, and allowed eight aberrations (four 
gains and four losses) that fell above the initial q-
value cutoff with the initial analysis to gain signifi-
cance in the combined data set. Despite this, some re-
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do not reach significance in the follow up study and 
vice versa (e.g. NF1, CDKN2C). 
(7)  Resequencing of selected candidates in additional 
samples uncovered somatic mutations of PTPRD (see 
below), CDKN2A, PTEN, RB1 and NF1. Several of 
these are bona fide inactivating mutations (e.g. non-
sense, frameshift, splice site), thus providing addi-
tional genetic evidence for somatic inactivation in 
human cancers. 
  Among the genes nominated as a novel candidate tumor 
suppressor gene by the glioma copy number analysis is 
PARK2. The gene encodes Parkin, an E3-ubiquitin ligase, 
mutations in which (including deletions) were shown by 
classical linkage analysis to account for the most common 
form of inherited juvenile Parkinson’s disease [73]. Loss-of-
heterozygosity on the long arm of chromosome 6, centered 
on 6q25-27, has been frequently described in human tumors, 
and  PARK2 (6q26) has previously been suggested to be a 
candidate tumor suppressor gene on the basis of heterozy-
gous (and rare homozygous) deletions in diverse cancers 
[74-76]. However, the somatic origin of these mutations had 
not been demonstrated, and tumor re-sequencing initially 
failed to reveal inactivating point mutations. 
  The short arm of chromosome 6 was shown in both GIS-
TIC glioma studies to harbor a highly significant recurrent 
region of loss. Although the number of contiguous probes 
significantly scoring as lost in these studies spans a large 
portion of 6q (essentially all of 6q scores as significant), the 
peak region defined by the set of contiguous probes with the 
smallest q-value contained only 3 genes: PARK2, PACRG 
and  QKI.  Based on these findings, Verriah et al. subse-
quently re-examined individual tumor sample copy number 
data from the TCGA set of 216 gliomas (as well as l98 colon 
cancer samples) [77]. These authors discovered loss of at 
least one allele of PARK2 in ~25% of each tumor type, with 
intragenic homozygous deletions within PARK2  in 2.3% 
gliomas (5 cases) and 6.1% colon carcinomas (6 cases). In 
addition, sequencing of 242 tumors identified 12 cases with 
point mutations (11 heterozygous), including a splice site 
mutation in a primary glioma and a nonsense mutation in a 
glioma cell line. Finally, the authors performed extensive 
functional validation in human cancer cell lines, demonstrat-
ing suppression of in vitro growth and colony formation and 
in vivo growth of cell line xenografts upon re-expression of 
wild-type but not several mutant PARK2 alleles, and only in 
cells with endogenous loss of PARK2 (cells expressing wild-
type PARK2 were not affected). Parkin had previously been 
shown to function as an E3 ubiquitin ligase, and the authors 
demonstrated wild-type but not cancer-specific mutant 
Parkin was able to direct the proteasomal-mediated degrada-
tion of Cyclin E, and that PARK2 knockdown led to the an 
increased fraction of cells in the S and G2-M phases of the 
cell cycle.  
 PTPRD, encoding a receptor tyrosine phosphatase, is a 
second candidate tumor suppressor gene identified by GIS-
TIC analysis. PTPRD was previously found to be deleted in 
both small cell and non-small cell lung cancer cell lines 
[78,79]. However, its proximity to CDKN2A/B, the high rate 
of homozygous deletions affecting 9p in lung cancer (~30%) 
and the identification of frequent germline copy number po-
lymorphisms also raised the possibility that PTPRD is part of 
a fragile site prone to recombination [67,78] and is not a true 
tumor suppressor gene. Initial GISTIC analysis of 371 pri-
mary lung adenocarcinomas identified 5 tumors with focal 
deletions affecting the 5’ untranslated region of PTPRD [52]. 
Sequencing of all PTPRD coding exons in 188 tumors re-
vealed somatic, heterozygous missense mutations in 11 sam-
ples (6%). Notably, sequencing of two other candidate genes 
encompassed by significant deletions (AUTS2 and PDE4D) 
for a total of 34 coding exons failed to uncover any muta-
tions in these genes. Although PTPRD  was not uniquely 
identified by the GISTIC analysis of gliomas, it was scored 
as one of the most significant candidate genes in the same 
data set using a different algorithm (RAE) [38]. Following 
up on these results, a subsequent re-analysis of the TCGA 
glioma data set revealed frequent (~40%) hemizygous or 
homozygous losses, most encompassing nearly all of chro-
mosome 9p. The majority of these (two-thirds) demonstrated 
loss of either PTPRD or CDKN2A/B. Although PTPRD loss 
was accompanied by co-deletion of CDKN2A/B in all but 
one case, for one-third of co-deleted samples,  a region of 
normal copy number separates the PTPRD and CDKN2A/B 
deletions (suggesting the possibility that each deletion was 
selected independently). Furthermore, two samples demon-
strated intragenic homozygous deletions within the PTPRD 
gene that are predicted to remove coding exons. Additional 
evidence for somatic inactivation of PTPRD was provided 
both by sequencing analysis, which uncovered eight somatic 
mutations, including a single nonsense mutation, and by 
methylation-specific PCR and bisulfite sequencing, which 
uncovered specific methylation of the PTPRD promoter in ~ 
one-third of primary gliomas analyzed (as well as a signifi-
cant fraction of breast and colon cancers). Finally, introduc-
tion of wild-type PTPRD (but not cancer-specific mutants) 
inhibited, and shRNA knockdown promoted, cell growth in 
vitro and in xenografts, possibly via  effects on the 
phosphorylation-dependent activation of STAT3.  
 For  both  PARK2 and PTPRD, the discovery of focal in-
tragenic microdeletions, somatic point mutations (and for 
PTPRD, promoter methylation) and tumor suppressor activ-
ity in functional assays provide compelling evidence for their 
specific inactivation during gliomagenesis. However, two 
features of both of these genes complicate their classification 
as TSGs with a highly significant role in gliomagenesis. 
First, more than 100 germline genomic variants overlapping 
PARK2 and PTPRD have been identified, including 46 copy 
number polymorphisms (e.g. more than 1kB in size) in 
PARK2 and 40 in PTPRD (the remaining consist of small 
insertions and deletions from 0.1 to 1kB in size) [55]. For 
PTPRD, three losses overlap coding exons, one with a fre-
quency of 3% (in the population examined). For PARK2, at 
least four losses eliminate coding exons, one at a frequency 
of ~5%. Although the initial genomic studies took steps to 
minimize the impact of germline polymorphisms on the se-
lection of candidate regions (for the lung adenocarcinoma 
study in particular, matched normal samples were used to 
determine copy number for the majority of tumor samples), 
it is surprising that inactivating germline deletions occurring 
at a significant frequency in the general population are not 
associated with a highly penetrant predisposition to cancer 
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overall population frequency of germline inactivating muta-
tions in bona fide tumor suppressor genes responsible for 
rare familial cancer predisposition syndromes). In addition, 
very few germline polymorphisms have been catalogued for 
established TSGs (Table 2). This may be particularly rele-
vant for PARK2, since most deletions are hemizygous, and 
the authors hypothesize that haploinsufficiency of PARK2 is 
sufficient to promote tumorigenesis. Second, although there 
is a precedent for heterozygous missense mutations leading 
to inactivation of protein function (e.g. the TP53 gene), gen-
erally this requires dominant-negative activity for the mutant 
protein or epigenetic loss of expression of the wild-type al-
lele. In both studies, overexpressed cancer-specific mutant 
Parkin or PTPRD proteins lacked the growth inhibitory ef-
fects of the wild-type protein in cells with loss of the en-
dogenous gene; however, there was no demonstration of 
potential dominant-negative activity by testing the effect of 
the mutants on cells wild-type for each protein. Furthermore, 
in tumors or cells with hemizygous mutations (deletions or 
point mutations), expression from the wild-type allele was 
not examined. 
The First X Chromosome Tumor Suppressor Genes: 
WTX and UTX 
  The discovery of WTX illustrates the power of genome-
wide copy number analysis when focused on a limited set of 
highly related tumors with a low background rate of genomic 
alterations [19]. Wilms tumor is the most common pediatric 
kidney cancer. Germline heterozygous genetic inactivation 
of the zinc finger transcription factor WT1 accounts for two 
forms of familial Wilms tumor (the second allele is inacti-
vated in the tumors), and somatic biallelic inactivation has 
been described in 5-10% of sporadic Wilms tumors 
[12,15,19]. In addition, activating mutations in the CTNBB1 
gene and epigenetic dysregulation of the IGF axis have been 
described in rare cases [80]. However, in the majority of 
cases, no specific genetic abnormalities had been identified. 
  To search for additional Wilms tumor genes, investiga- 
tors performed oligonucleotide array-based CGH on a collec- 
tion of 51 primary Wilms tumor specimens. In marked con- 
trast to most adult cancers, the array CGH profile in Wilms  
tumor was remarkably stable, with very few gains, single   
copy losses or homozygous deletions. As a result, focal ho- 
mozygous deletions at Xq11.1 spanning just 1-3 probes were  
able to be clearly identified in 5/26 tumors, with the minimal  
common area of deletion implicating a previously uncharac- 
terized gene, which was renamed WTX. Sequencing of the  
coding region in additional tumors uncovered six truncating  
mutations; no mutations were present in matched normal   
tissue or 269 unmatched normal DNA samples. Notably, in  
Wilms tumors from female patients, inactivating mutations  
exclusively target the active X chromosome through a single  
hit mechanism, with expression of the intact allele elimi- 
nated by X inactivation. Furthermore, expression of WTX is  
restricted to the renal stem cell population that is the pre- 
sumed cell of origin of Wilms tumors. Although cell lines  
with endogenous loss of WTX are not available, the authors  
showed that overexpression in immortalized kidney cells   
suppressed colony formation through induction of apoptosis.  
  By comparison to the relatively focused analysis of a 
limited number of tumors of a single type, analysis of 1,390 
cancer cell lines and primary tumors by a combination of 
array-based copy number analyses and candidate gene re-
sequencing uncovered 39 inactivating mutations in the his-
tone H3 lysine 27 demethylase gene UTX, also located on 
the X chromosome [81]. The mutations comprised 16 homo-
zygous deletions (13 intragenic microdeletions) and 23 point 
mutations (nine nonsense, 12 frameshift and two splice site 
mutations). In contrast to WTX, mutations in which so far 
appear limited to Wilms tumors, UTX mutations were dis-
covered in multiple tumor types. Furthermore, UTX has been 
shown to escape X inactivation in females. Instead, a Knud-
sen two-hit model of inactivation is likely, on the basis of 
specific loss of the second UTX allele in the majority of af-
fected cell lines derived from cancers in females, and con-
current loss of the UTX  Y chromosome paralogue UTY in 
cell lines derived from cancers in males. Finally, re-
expression of wild-type UTX significantly prolonged the in 
vitro doubling time of two UTX mutant cell lines but not a 
wild-type cell line. Although no correlation was observed 
between UTX status and global H3K27 trimethylation, rein-
troduction of UTX resulted in decreased H3K27 trimethyla-
tion of differentially expressed genes.  
  The combined genetic and functional data provide very 
compelling evidence for a bona fide tumor suppressor func-
tion for both WTX and UTX.  In contrast to PTPRD  and 
PARK2, highly frequent inactivating frameshifts and non-
sense mutations were uncovered;  no germline polymor-
phisms overlapping either WTX or  UTX  have previously 
been described; and no instances of inactivating mutations or 
deletions were identified in hundreds of normal DNA sam-
ples analyzed in each study.  
Acute Lymphoblastic Leukemia (ALL) and PAX5 
 As  with  WTX, the discovery of inactivating mutations in 
PAX5 and other B-lymphocyte lineage determination genes 
in pediatric ALL illustrates the power of copy number analy-
sis for uncovering critical tumor suppressor genes, particu-
larly when focused on a single cancer type with a relatively 
low background rate of copy number alterations [82,83]. In 
contrast to Wilms tumor, tumor initiating genetic lesions in 
many pediatric ALLs have been defined, including chromo-
somal translocations (e.g. TEL-AML1, E2A-PBX1, BCR-
ABL, E2A-PBX1) and rearrangements involving MLL [84]. 
However, none of these lesions yields a full leukemic pheno-
type in animal models, suggesting a requirement for addi-
tional cooperating alterations. To search for such genomic 
alterations, Mullighan et al. interrogated the purified leuke-
mic blasts from 242 cases of pediatric ALL using high-
resolution SNP arrays. Copy number was determined in a 
novel fashion, by normalizing each probe to the intensity of 
probes derived from known diploid regions within the same 
sample’s genome (as determined by cytogenetics) prior to 
segmentation. Segments comprised of less than 3 SNPs were 
filtered out, and the remaining segments that contained an 
average log2 copy number ratio > 0.2 or < -0.2 were scored 
as gains or losses. Germline copy number variants were 
eliminated for 228 samples by using the available paired 
remission sample as the copy number reference, and for the 
14 unmatched samples by eliminating probes that appeared 
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  Notably, the mean number of copy number alterations 
per tumor is only 6.46, with amplifications outnumbering 
deletions ~2:1 (this is the opposite of what was observed for 
gliomas). Among 54 recurrently deleted regions were previ-
ously identified bona fide tumor suppressor genes in leuke-
mias, including CDKN2A, ATM, and RB1. However, most 
strikingly were  91 deletions in 7 regulators of normal B-
lymphocyte development, limited to B-lymphocyte-derived 
ALL cases (n=192). Among these were 57 tumors with dele-
tions of PAX5 (53 single copy, 3 biallelic, 1 internal amplifi-
cation, 23 intragenic), resulting in loss of expression of the 
mutated allele or expression of internally deleted or trun-
cated proteins lacking critical functional domains. Impor-
tantly, since the majority of PAX5 mutations were heterozy-
gous, the authors tested the functional effects of a panel of 
cancer-specific mutant PAX5 target genes in the presence of 
the wild-type protein. In all cases, the mutant proteins inhib-
ited transcriptional activation of transfected reporter con-
structs and known endogenous PAX5  target genes. Using a 
similar analysis, the same authors recently demonstrated 
recurrent intragenic deletions in the B-lineage developmental 
regulator  IKZF1  in more than 80% of BCR-ABL  positive 
ALL cases [83]. The high frequency of genetic inactivation 
of several genes comprising the same pathway (e.g. B line-
age determination), the demonstration of dominant-negative 
activity, the lack of previously described germline variants 
and the use of matched normal reference samples to confirm 
the somatic origin of the observed mutations provide strong 
evidence for a highly frequent and penetrant tumor suppres-
sor role for these genes.  
CONCLUSIONS 
  In no other field of biology or medicine has the potential 
value of genome-wide approaches been as thoroughly ex-
ploited as human cancer genetics. An unprecedented body of 
data describing human tumor copy number aberrations has 
been accumulated in recent years, leading to the identifica-
tion of many recurrent regions of gains and losses that may 
harbor critical cancer genes. These studies have been carried 
out on a variety of array platforms, using a variety of algo-
rithms for identifying genomic regions, different thresholds 
for scoring gains and losses and various criteria for prioritiz-
ing candidate genes and determining statistical significance. 
As discussed, given the particular challenges associated with 
detecting genomic losses (compared to gains), accurate de-
tection of single-copy and homozygous deletions may de-
pend on the specific assumptions and methodologies of the 
individual approaches. Therefore, knowledge of how each 
method specifically manages the detection of losses can be 
helpful in choosing individual candidates for further valida-
tion from large lists of genes. 
  When evaluating the evidence supporting a tumor sup-
pressor role for a candidate gene identified through array-
based copy number analysis, several critical questions need 
to be considered. Which array platform was used? What was 
the density of probes? What was the nature of the reference 
samples used to determine copy number? If segmentation 
was used, how were very small segments considered? What 
types of thresholds were used to select losses? Were germ-
line copy number variants considered? Was the background 
rate of losses estimated (and how)? Were individual candi-
dates genes validated with deeper analysis and functional 
assays? Do the mutations (deletions, point mutations) disrupt 
both alleles? If not, is the wild-type allele expressed?  
  The shear volume of cancer genomic data will continue 
to increase as newer technologies, such as whole cancer ge-
nome re-sequencing and genome-wide analysis of epigenetic 
DNA modifications, are refined to permit their application to 
large numbers of samples. This overview of array-based 
copy number analysis hopefully provides a framework for 
evaluating the large number of candidate tumor suppressor 
genes likely to emerge from these technologies in the near 
future. 
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